Physician

Adnan Saeed Malik, M.D.

According to 2025 Medicare claims, Adnan Malik, M.D. (NPI: 1699829234) practices advanced heart failure and transplant cardiology in the York-Hanover, PA market, with the plurality of this provider's patient population coming from York, PA. This provider's primary affiliated billing organization is GOOD SAMARITAN PHYSICIAN SERVICES (NPI: 1497521702; TIN: 251832359) and primary practice location at 17403-3676. Malik is affiliated with the WellSpan Population Health Services (ACO ID: A2500), participating under the MSSP model.

Malik's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 364 traditional Medicare patients, billed 629 HCPCS/CPT codes, and received $48,135 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 783 prescription claims across 171 beneficiaries totaling $781,970 in drug costs, led by Vyndamax (Tafamidis). 2022 DME data shows 42 claims. Open Payments data shows 12 records totaling $9,299. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $159,673 to $781,970. For DME billing, reported payments moved up and down with repeated peaks and valleys, starting at $15,649 and ending at $19,752.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	457	1,154	$63,229
2016	892	1,702	$70,570
2017	1,509	2,274	$80,674
2018	1,214	1,870	$101,381
2019	832	1,369	$90,192
2020	647	1,148	$75,212
2021	753	1,241	$87,417
2022	616	1,155	$81,197
2023	504	924	$73,266
2024	364	629	$48,135

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	221	3,468	$159,673
2016	245	1,322	$40,831
2017	250	1,129	$57,940
2018	263	1,254	$68,353
2019	246	1,083	$155,518
2020	236	1,084	$167,994
2021	218	1,020	$185,056
2022	223	1,203	$255,233
2023	203	965	$566,342
2024	171	783	$781,970

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	70	711	$69,116
2016	11	257	$20,474
2017	N/R	47	$4,912
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	12	$26,969
2022	N/R	42	$4,637
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	57	59	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	97	119	$90
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	49	103	$89
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	43	63	$59
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	77	83	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	26	780	$579,046
Entresto	Sacubitril/Valsartan	89	5,040	$100,854
Eliquis	Apixaban	38	2,220	$43,368
Jardiance	Empagliflozin	21	1,170	$20,088
Potassium Chloride	Potassium Chloride	15	945	$1,804

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$249	ABIOMED
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$9,050	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adnan Saeed Malik, M.D.?

Tedicare shows public-source Medicare data for Adnan Saeed Malik, M.D. (NPI 1699829234), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adnan Saeed Malik, M.D. have ACO affiliation data?

Adnan Saeed Malik, M.D. is shown with ACO affiliation data for WellSpan Population Health Services (MSSP, ACO ID A2500).

What billing organization is linked to Adnan Saeed Malik, M.D.?

Adnan Saeed Malik, M.D. is linked to GOOD SAMARITAN PHYSICIAN SERVICES (billing NPI 1497521702) in the available physician profile data.

Does Adnan Saeed Malik, M.D. have Open Payments data?

Adnan Saeed Malik, M.D. has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.